CA2712750A1 - Aldh-2 inhibitors in the treatment of addiction - Google Patents

Aldh-2 inhibitors in the treatment of addiction Download PDF

Info

Publication number
CA2712750A1
CA2712750A1 CA2712750A CA2712750A CA2712750A1 CA 2712750 A1 CA2712750 A1 CA 2712750A1 CA 2712750 A CA2712750 A CA 2712750A CA 2712750 A CA2712750 A CA 2712750A CA 2712750 A1 CA2712750 A1 CA 2712750A1
Authority
CA
Canada
Prior art keywords
phenyl
chromen
hydroxyphenyl
compound
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2712750A
Other languages
English (en)
French (fr)
Inventor
Yaroslav Bilokin
Elfatih Elzein
Jeff Zablocki
Michael Organ
Thao Perry
Tetsuya Kobayashi
Matthew Abelman
Rao Kalla
Peidong Fan
Ivan Diamond
Robert Jiang
Maria Pia Arolfo
Xiaofen Li
Lina Yao
Zhan Jiang
Wing Ming Keung
Guoxin Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Endowment for Research in Human Biology Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2712750A1 publication Critical patent/CA2712750A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA2712750A 2008-01-24 2008-01-24 Aldh-2 inhibitors in the treatment of addiction Abandoned CA2712750A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/051862 WO2009094028A1 (en) 2008-01-24 2008-01-24 Aldh-2 inhibitors in the treatment of addiction

Publications (1)

Publication Number Publication Date
CA2712750A1 true CA2712750A1 (en) 2009-07-30

Family

ID=39731733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2712750A Abandoned CA2712750A1 (en) 2008-01-24 2008-01-24 Aldh-2 inhibitors in the treatment of addiction

Country Status (13)

Country Link
EP (1) EP2254878A1 (es)
JP (1) JP2011510072A (es)
KR (1) KR20100130589A (es)
CN (1) CN101925590A (es)
AU (1) AU2008348372A1 (es)
BR (1) BRPI0822129A2 (es)
CA (1) CA2712750A1 (es)
EC (1) ECSP10010417A (es)
IL (1) IL207127A0 (es)
MA (1) MA32095B1 (es)
MX (1) MX2010008111A (es)
WO (1) WO2009094028A1 (es)
ZA (1) ZA201004671B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018009B2 (en) 2022-06-14 2024-06-25 Amygdala Neurosciences, Inc. ALDH-2 inhibitor compounds and methods of use

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161648A (zh) * 2011-02-18 2011-08-24 中国药科大学 具有选择性雌激素受体调节活性的异黄酮类化合物的制备方法及其用途
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
TWI468403B (zh) 2011-08-30 2015-01-11 Gilead Sciences Inc 用於治療成癮之aldh-2抑制劑
WO2019079209A1 (en) * 2017-10-16 2019-04-25 Amygdala Neurosciences, Inc. POLYTHERAPY FOR THE PREVENTION OF AN ADDICTION
CN108276374B (zh) * 2018-03-29 2020-01-31 天津科技大学 黄酮类芳香化酶抑制剂及其制备方法与应用
CN110922394B (zh) * 2019-11-21 2021-04-06 中国科学院宁波材料技术与工程研究所 一种基于天然黄酮类化合物的生物基本征阻燃环氧树脂前驱体及其制备方法和应用
WO2023235753A2 (en) * 2022-05-31 2023-12-07 University Of Maryland, Baltimore Aldh2 inhibitors and methods of use thereof
WO2023244563A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU162377B (es) * 1970-05-27 1973-02-28
US4166862A (en) * 1971-05-25 1979-09-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Animal feed containing anabolic isoflavones
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
CA2334830A1 (en) * 1998-05-12 1999-11-18 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
AU2002367953C1 (en) * 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
CA2491089A1 (en) * 2002-06-27 2004-01-08 The Endowment For Research In Human Biology, Inc. Compounds useful for the inhibition of aldh
EP2277595A3 (en) * 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
PL377180A1 (pl) * 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
RU2008151762A (ru) * 2006-07-27 2010-06-27 Си Ви Терапьютикс, Инк. (Us) Adlh-2 ингибиторы для лечения аддикции
AU2008323953A1 (en) * 2007-11-06 2009-05-14 Gilead Palo Alto, Inc. ALDH-2 inhibitors in the treatment of psychiatric disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018009B2 (en) 2022-06-14 2024-06-25 Amygdala Neurosciences, Inc. ALDH-2 inhibitor compounds and methods of use

Also Published As

Publication number Publication date
BRPI0822129A2 (pt) 2015-06-23
AU2008348372A1 (en) 2009-07-30
WO2009094028A1 (en) 2009-07-30
ECSP10010417A (es) 2010-11-30
CN101925590A (zh) 2010-12-22
IL207127A0 (en) 2010-12-30
JP2011510072A (ja) 2011-03-31
KR20100130589A (ko) 2010-12-13
MX2010008111A (es) 2010-11-30
EP2254878A1 (en) 2010-12-01
ZA201004671B (en) 2011-03-30
MA32095B1 (fr) 2011-02-01

Similar Documents

Publication Publication Date Title
US20080032995A1 (en) Aldh-2 inhibitors in the treatment of drug addiction
US8158810B2 (en) ALDH-2 inhibitors in the treatment of addiction
CA2712750A1 (en) Aldh-2 inhibitors in the treatment of addiction
US10507215B2 (en) Compounds for the treatment of addiction
CA2704981A1 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
US7951813B2 (en) Quinazolinone derivatives as ALDH-2 inhibitors
US20080207610A1 (en) Aldh-2 inhibitors in the treatment of addiction
AU2012300209B2 (en) ALDH-2 inhibitors in the treatment of addiction
CN101627024A (zh) 成瘾治疗中的aldh-2抑制剂
AU2016244324A1 (en) Compounds for the treatment of addiction

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130124